脂肪、纤维化与未来：探索MAFLD/MASH的迷宫 - Suppr

Suppr

超能文献

Fat, fibrosis, and the future: navigating the maze of MASLD/MASH.

作者信息

Friedman Scott L

出版信息

J Clin Invest. 2025 Apr 1;135(7):e186418. doi: 10.1172/JCI186418.

DOI:10.1172/JCI186418

PMID:40166940

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11957683/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f48/11957683/4735ea79bac1/jci-135-186418-g273.jpg

相似文献

Fat, fibrosis, and the future: navigating the maze of MASLD/MASH.脂肪、纤维化与未来：探索MAFLD/MASH的迷宫

J Clin Invest. 2025 Apr 1;135(7):e186418. doi: 10.1172/JCI186418.

NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.非酒精性脂肪性肝病（MASLD）/非酒精性脂肪性肝炎（MASH）：是否有必要进行标记？全面的叙述性综述。

Int J Mol Sci. 2024 Aug 2;25(15):8462. doi: 10.3390/ijms25158462.

Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis.体重减轻对代谢功能障碍相关脂肪性肝炎和肝纤维化的影响。

Curr Diab Rep. 2025 Feb 18;25(1):23. doi: 10.1007/s11892-025-01579-1.

BRUCE liver-deficiency potentiates MASLD/MASH in PTEN liver-deficient background by impairment of mitochondrial metabolism in hepatocytes and activation of STAT3 signaling in hepatic stellate cells.BRUCE肝脏缺乏通过损害肝细胞中的线粒体代谢和激活肝星状细胞中的STAT3信号通路，在PTEN肝脏缺乏背景下增强了代谢相关脂肪性肝病/非酒精性脂肪性肝炎。

bioRxiv. 2024 Sep 14:2024.09.13.611500. doi: 10.1101/2024.09.13.611500.

Choline-deficient, high-fat diet-induced MASH in Göttingen Minipigs: characterization and effects of a chow reversal period.胆碱缺乏、高脂肪饮食诱导的哥廷根小型猪 MASH：特征描述及膳食逆转期的影响。

Am J Physiol Gastrointest Liver Physiol. 2024 Oct 1;327(4):G571-G585. doi: 10.1152/ajpgi.00120.2024. Epub 2024 Jul 23.

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。执行摘要。

Diabetologia. 2024 Nov;67(11):2375-2392. doi: 10.1007/s00125-024-06196-3.

Diagnostic Accuracy of Golgi Protein 73 (GP73) for Liver Fibrosis Staging in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Scoping Review and Cohort Study.高尔基体蛋白73（GP73）对代谢功能障碍相关脂肪性肝病肝纤维化分期的诊断准确性：一项范围综述和队列研究

Diagnostics (Basel). 2025 Feb 24;15(5):544. doi: 10.3390/diagnostics15050544.

Ketogenesis protects against MASLD-MASH progression through mechanisms that extend beyond overall fat oxidation rate.生酮作用通过超出总体脂肪氧化率的机制来预防代谢相关脂肪性肝病-代谢功能障碍相关脂肪性肝病的进展。

bioRxiv. 2024 Dec 21:2024.10.17.618895. doi: 10.1101/2024.10.17.618895.

Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.用于诊断代谢功能障碍相关脂肪性肝病的质子密度脂肪分数

Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001318.

Single-cell landscape of peripheral immune cells in MASLD/MASH.代谢相关脂肪性肝病/非酒精性脂肪性肝炎中外周免疫细胞的单细胞图谱

Hepatol Commun. 2025 Apr 21;9(5). doi: 10.1097/HC9.0000000000000643. eCollection 2025 May 1.

本文引用的文献

Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050.2020年至2050年美国成年人中代谢功能障碍相关脂肪性肝病的估计负担

JAMA Netw Open. 2025 Jan 2;8(1):e2454707. doi: 10.1001/jamanetworkopen.2024.54707.

Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease.数据驱动的聚类分析识别出代谢功能障碍相关脂肪性肝病的不同类型。

Nat Med. 2024 Dec;30(12):3624-3633. doi: 10.1038/s41591-024-03283-1. Epub 2024 Dec 9.

Identifying patient subgroups in MASLD and MASH-associated fibrosis: molecular profiles and implications for drug development.鉴定 MASLD 和 MASH 相关纤维化中的患者亚组：分子谱及对药物研发的意义。

Sci Rep. 2024 Oct 7;14(1):23362. doi: 10.1038/s41598-024-74098-w.

Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen.肥胖增加 2 型糖尿病青年患者肝纤维化的风险：需要进行筛查。

Obesity (Silver Spring). 2024 Oct;32(10):1967-1974. doi: 10.1002/oby.24130.

The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.2 型糖尿病患者中非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球流行病学。

Clin Gastroenterol Hepatol. 2024 Oct;22(10):1999-2010.e8. doi: 10.1016/j.cgh.2024.03.006. Epub 2024 Mar 21.

The Global Epidemic of Metabolic Fatty Liver Disease.代谢性脂肪性肝病的全球流行

Curr Cardiol Rep. 2024 Apr;26(4):199-210. doi: 10.1007/s11886-024-02025-6. Epub 2024 Feb 20.

Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.回复：关于新的脂肪性肝病命名的多学会德尔菲共识声明。

Hepatology. 2024 Mar 1;79(3):E93-E94. doi: 10.1097/HEP.0000000000000696. Epub 2023 Nov 20.

Global burden of liver disease: 2023 update.全球肝病负担：2023 年更新。

J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27.

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.非酒精性脂肪性肝炎相关肝细胞癌：发病机制与治疗。

Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):487-503. doi: 10.1038/s41575-023-00754-7. Epub 2023 Mar 17.

Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties.非酒精性脂肪性肝病的医疗保健和社会经济学成本：一个应对不确定性的全球框架。

J Hepatol. 2023 Jul;79(1):209-217. doi: 10.1016/j.jhep.2023.01.026. Epub 2023 Feb 4.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验